In re Bystolic Antitrust Litigation

  1. March 24, 2023

    Bystolic 'Side Deals' Deemed Legit, Not Generic Delay Plans

    Drug wholesalers, retailers and employee benefit funds made none of the complaint changes they'd need to, to undermine the legitimacy of drug supply and development deals an AbbVie predecessor struck settling patent infringement litigation staving off generic versions of hypertension drug Bystolic, according to a ruling unsealed Friday.

  2. January 24, 2022

    Pharma Cos. Get Bystolic Generic Delay Claims Tossed

    A New York federal judge dismissed claims brought against AbbVie and other pharmaceutical firms by direct purchasers including Walgreens and CVS as well as claims brought by end payers who accused the drugmakers of conspiring to keep generic forms of the blockbuster hypertension drug Bystolic off the market.

  3. September 21, 2021

    AbbVie Calls Retailers' Bystolic Generic Delay Claims Flawed

    AbbVie has urged a New York federal judge to toss complaints from retailers CVS and Walgreens accusing the drugmaker of plotting to keep generic forms of the blockbuster drug Bystolic off the market.

  4. February 09, 2021

    AbbVie, Others Move To End Generic Bystolic Antitrust Claims

    AbbVie Inc. and subsidiaries have fired back against a consolidated class action accusing the drug giant of reaping millions of dollars in profit by paying competitors to delay generic forms of the blood pressure drug Bystolic, arguing in a dismissal motion that some buyers lack standing to assert various state antitrust and consumer-protection claims.